Dysplastic Barrett's esophagus is a condition that offers multiple diagnostic and therapeutic challenges. The diagnosis of dysplasia within Barrett's esophagus currently relies on periodic endoscopic surveillance with multiple biopsies, a methodology limited by random sampling error, inconsistent histopathologic interpretation and delay in diagnosis. Optical spectroscopic and imaging techniques have the potential to identify dysplastic or early neoplastic lesions in real-time. These diagnostic modalities are needed to enhance the endoscopic surveillance of Barrett's esophagus in the future as well as help to define lesions for endoscopic therapy. Esophagectomy has been the standard of care for Barrett's esophagus with high-grade dysplasia although it is a procedure associated with significant morbidity and mortality. Minimally invasive endoscopic ablative therapies are attractive and less morbid alternatives to esophagectomy, with promising results obtained from the use of light-activated drugs (i.e., photodynamic therapy). The combination of novel optical diagnostic techniques and therapies will provide the endoscopist with much needed tools that can considerably enhance the management of patients with Barrett's esophagus. This article reviews the current status and future prospects of optical-based modalities for diagnosis and therapy of dysplastic Barrett's esophagus.
Introduction
Barrett's esophagus (BE) predisposes to esophageal adenocarcinoma (ACA), a cancer with one of the fastest rising incidence rates over the past decade and a highly lethal malignancy once symptomatic (1, 2) . Although BE can usually be recognized at endoscopy, visual clues for dysplasia, the primary marker for predicting progression to invasive malignancy, are often lacking. Practice guidelines recommend periodic endoscopic surveillance with multiple biopsies in an attempt to identify dysplastic and early cancerous lesions at a time when therapeutic intervention can be beneficial (3). This approach, however, is hindered by random sampling error, inter-and intra-observer variation in histologic interpretation, inflammation-induced artifacts, pathology-associated costs and delay in diagnosis. Studies in which patients have undergone a standard surveillance biopsy protocol, followed by esophagectomy, have found the surveillance programs to miss as many as 43-57% of endoscopically occult ACAs in patients with high grade dysplasia (HGD) (4, 5) . These studies highlight that current surveillance strategies are far from perfect, often miss important lesions and raise doubts about the ability of surveillance endoscopy to benefit patients with dysplastic BE. These limitations, in part, have generated con-siderable interest and effort in developing optical spectroscopic and imaging techniques for enhancing the endoscopic surveillance of BE (6) (7) (8) . Optical-based modalities measure specific light-tissue interactions, such as fluorescence, elastic scattering, and Raman (inelastic) scattering, which can provide rapid and non-destructive diagnostic information about the molecular and structural status of tissue. The potential benefits of these techniques are numerous, including surveying more of the Barrett's segment than that afforded by conventional biopsy, objective interpretation of tissue pathology, and targeting, if not replacing, biopsies to areas more likely to harbor dysplastic or cancerous lesions.
As regards treatment of BE with HGD, options are currently limited to a passive approach of intensive and costly surveillance endoscopy until the detection of ACA, or an aggressive approach of surgically removing the esophagus to prevent the development of cancer (3). Both of these approaches have serious drawbacks in terms of challenges to the patient and physician. In particular, surgical therapy is fraught with concerns. In recent studies, HGD has been found to have a benign course in many patients and does not inevitably evolve to cancer as once believed. If incident cancers are excluded, a study with a mean follow-up of seven years has shown that only 16% of patients with HGD develop ACA (9). In addition, the recently presented results of the first multi-center randomized controlled trial of photodynamic therapy (PDT) for BE with HGD found that the latter disappeared in the control group in 39% of the patients at a two-year follow-up (10). These studies emphasize that there are patients with BE and HGD in whom surgery may be overly aggressive as therapy. Moreover, patient morbidity and mortality following esophagectomy, even in experienced hands, ranges from 30-40% and 1.7-10%, respectively (11, 12) . PDT in this setting represents an attractive and less invasive alternative, with promising results regarding eradication of dysplasia in BE (10).
This article focuses on the current status and future trends of optical diagnostic techniques for the detection of dysplastic BE, and PDT for its eradication.
Optical Diagnostics
Fluorescence Spectroscopy
Principles and Instrumentation
Fluorescence occurs when ultraviolet (UV) or visible light of short wavelengths is absorbed by tissue which then reemits light of longer wavelengths. Autofluorescence is a term used to describe fluorescence emanating from naturally occurring tissue molecules such as aromatic amino acids, collagen and porphyrins (endogenous fluorophores). Each group of fluorophores is characterized by distinct excitation and fluorescence emission wavelength ranges (Table I) , although it is common for a single excitation wavelength to excite several fluorophores and for their emission bandwidths to overlap, resulting in a broad and relatively featureless fluorescence spectrum.
Different stages of tissue pathology are associated with alterations in content, spatial distribution and/or metabolic activity of various fluorophores, which ultimately affect the overall fluorescence lineshape (13). Excitation of Barrett's epithelium with wavelength(s) in the violet-blue range usually generates a spectrum which demonstrates a relative increase in the red-to-green fluorescence intensity ratio when compared to normal squamous mucosa. Although spectral variability exists, this ratio is seemingly accentuated as metaplastic Barrett's epithelium evolves toward dysplasia and adenocarcinoma ( Fig. 1 ). Also shown in Figure  1 are distortions in the fluorescence spectrum induced by chromophores, which are tissue molecules that absorb light without re-emission of fluorescence. In gastrointestinal (GI) tissue, the major chromophore in the visible range (400-700 nm) is hemoglobin, which is responsible for the spectral dip (decrease in fluorescence intensity) at 580 nm. Distortions such as these can be mathematically simulated and extracted to reveal the intrinsic fluorescence of tissue that is unaffected by absorption and scattering events (14) . Recent analysis of the intrinsic autofluorescence spectra of BE via modeling techniques suggests that low collagen and high NAD(P)H fluorescence characterize HGD lesions when compared with non-dysplastic BE tissues (15).
Tissue fluorescence may be enhanced following administration of an exogenous fluorophore, which is ideally highly selective for dysplastic and cancerous tissues. To date, photosensitizers used in photodynamic therapy, such as porfimer sodium and 5aminolevulinic acid (5-ALA), have been primarily exploited, many of which fluoresce and demonstrate some selectivity for neoplastic tissues. Drug induced fluorescence is advantageous for several reasons: i) the fluorescent signal is strong and less ambiguous relative to autofluorescence, and so simpler and cheaper instrumentation can be used for its detection; and ii) the optimal excitation and emission wavelengths of these agents are known a priori. However, the success of this approach is highly dependent on the degree of selective localization of the drug within tissues of interest and the determination of the optimal drug dose, mode of administration, and time delay to performing the spectroscopic measurements, which may vary from patient to patient. Furthermore, side effects, cost and regulatory issues related to these drugs can be problematic. Figure 2 is a simplified schematic of a fluorescence point spectroscopic device. In practice, a fiberoptic probe is introduced into the accessory channel of a standard endoscope and placed gently in contact with the tissue surface. A typical probe consists of a central optical fiber delivering excitation light to the tissue and a surrounding circular array of optical fibers collecting the emitted fluorescence. The excitation source can be a laser or a wavelength-filtered lamp. At the excitation wavelength(s) typically used, the sampling depth of the light into tissue primarily probes the mucosa, the critical layer of interest. The collected fluorescent light is then separated into its component wavelengths and corresponding intensities by a spectrograph, with display of the fluorescence spectrum as an intensity versus wavelength line-shape on the computer monitor.
These line-shapes or spectra can be evaluated for their diagnostic value using a variety of empirical, statistical or modelbased algorithms. Spectral diagnosis is typically compared to histologic diagnosis as the gold standard to determine sensitivity and specificity of these algorithms. Empiric algorithms use specific spectral features, for example, calculating the intensity ratio of two fluorescence emission wavelength bands to determine a threshold that differentiate between tissue types. Although easy to implement, empiric algorithms do not make use of the full spectral information content and may be diagnostically less discriminative. Multivariate statistical classification techniques, such as principal component analysis, discriminant analysis and artificial neural networks, require significant data preprocessing but may be sensitive to subtle spectral differences between tissue types. Model-based algorithms are difficult to implement, require assumptions, but provide insights as to the biochemical origins of the observed spectral differences between tissue categories. Regardless of the analytical technique used, diagnostic algorithms derived from these methods can potentially be automated, so that the collection and input of an unknown tissue spectrum into these computerized algorithms ultimately provides a rapid diagnosis of tissue based on its spectral characteristics.
Endoscopic Applications
A summary of selected in vivo autofluorescence and druginduced fluorescence spectroscopic studies in BE is shown in We have yet to fully exploit the potential of autofluorescence spectroscopy in BE. For instance, the excitation and emission wavelengths that optimally characterize dysplastic lesions in BE have not been determined, although the recent application of fast excitation-emission matrices (fast EEM) instruments in vivo that allow assessment of multiple excitation wavelengths in rapid fashion will help to define these parameters (14) . Mechanistic studies performed on ex vivo specimens using confocal microscopy, microspectrofluorimetry and more rigorous EEM instruments can be helpful in identifying optimal excitation and emission wavelengths that are not known a priori, although caution is warranted since results obtained ex vivo may not translate to in vivo settings due to altered microvasculature and metabolic changes associated with these different tissue states. In addition to the prevailing steady-state fluorescence measurements, timeresolved fluorescence spectroscopy (TRFS) may provide further diagnostic information. TRFS measures the fluorescence intensity decay as a function of time at a given emission wavelength following a brief pulse of excitation light (~10 ns). Barrett's ACA generally produces a faster decay than non-dysplastic BE, but initial analysis of TRFS data indicates that it may not be able to achieve sensitivity and specificity above 60% in separating high-risk from low-risk BE (22).
A limited number of small-scale studies are available regarding fluorescence spectroscopy aided by exogenous fluorophores in BE. The first in vivo study used a low dose of the photosensitizer Photofrin (QLT Therapeutics, Vancouver, Canada), which contains porphyrins that emit characteristic red fluorescence peaks (630 and 690 nm) and are generally retained in neoplastic tissue to a higher degree than in normal tissue (23). Following 405 nm excitation, fluorescence spectra were collected and intensity ratios calculated as the quotient of Photofrin fluorescence (at 630 nm) divided by the autofluorescence background of tissue (at 500 nm). Spectra with fluorescence ratios above 0.55 had a high probability of malignancy but ratios below 0.55 were more difficult to categorize because of considerable overlap between normal mucosa, Barrett's epithelium with or without dysplasia, and malignant tissue. This small study of 5 patients was an initial step in the assessment of drug-induced fluorescence in the esophagus in vivo, although Photofrin seemed limited in its ability to discriminate between non-dysplastic and dysplastic lesions in BE.
Recently, there has been interest in using 5-ALA which is a substrate in the heme biosynthetic pathway. 5-ALA induces the formation of protoporphyrin IX (PPIX), an endogenous fluorophore emitting in the red (625-725 nm), which preferentially accumulates in dysplastic and malignant tissues due to an imbalance in the metabolic enzymes involved in porphyrin biosynthesis. In general, these tissues demonstrate elevated porphobilinogen deaminase levels and decreased ferrochelatase activity, resulting in greater accumulation of PPIX in neoplastic as opposed to normal cells (24). Furthermore, unlike Photofrin, 5-ALA-induced PPIX undergoes rapid metabolic breakdown resulting in a low incidence of side effects and short duration of skin photosensitivity.
Using 5-ALA (10 mg/kg orally) followed by fluorescence spectroscopy 3 h later, Brand et al. (25) reported a sensitivity of 77% and a specificity of 71% in differentiating HGD from non-dysplastic tissues in 20 BE patients. Ortner et al. (26) performed spectroscopy 1-2 h later following topical administration of 5-ALA (500 mg spray) onto the Barrett's mucosa in 53 patients. Tissues with LGD were discriminated from non-dysplastic Barrett's mucosa with moderate sensitivity (76%) and specificity (63%). These results are in contrast to the low detection rate for LGD achieved using autofluorescence spectroscopy.
Fluorescence spectroscopy aided by 5-ALA and other drugs is at an early stage of clinical investigation. Studies are needed to determine the optimal diagnostic parameters, the effectiveness of drug-induced fluorescence in randomized controlled trials, and any added benefit compared to the simpler method of autofluorescence.
Fluorescence Imaging

Principles and Instrumentation
The sampling yield is increased with point spectroscopic systems since multiple optical measurements ("optical biop-sies") can be collected during the interval it takes to obtain a single pinch biopsy. The optical probe, however, samples only a small volume of tissue (~1-2 mm 3 ) and is directed to the Barrett's mucosa in a somewhat random fashion, akin to conventional biopsy. Limitations inherent to point spectroscopic techniques have generated interest in developing fluorescence imaging devices where large areas of the mucosal surface can be assessed, with a field of view approaching that of a conventional endoscope. Fluorescence images can be acquired, for instance, by capturing selected fluorescence emission bands with special optical filters and sensitive cameras. There are several fiber-optic fluorescence imaging devices currently undergoing evaluation in BE and other sites (8, 27) . For example, the second generation Light-Induced Fluorescence Endoscopy system (LIFE-GI, Xillix Technologies Corp., Richmond, BC, Canada) uses blue light excitation (400-450 nm) and two intensified charged-coupled device (CCD) cameras to detect autofluorescence emitted in the green (490-560 nm) and in the red (630-750 nm) ( Fig. 3 ) (27). The CCD cameras are incorporated in a detachable lightweight module, which connects to the eyepiece of a conventional fiber-optic endoscope. The digitized fluorescence images are combined to produce a false-color composite image in real-time, where normal tissue typically appears green/cyan and abnormal tissue appears red ( Fig. 4) . It currently takes four seconds for the current system to alternate between white-light endoscopy (WLE) and LIFE, but upcoming versions will use even more compact camera modules and allow the switch to be completed in one second. Diagnostic sensitivity and specificity are determined by correlating positive (red fluorescence) and negative (green/cyan fluorescence) images with histopathologic diagnosis of corresponding biopsies. Another fiber-optic fluorescence imaging device consists of an incoherent light source (D-Light, Storz, Tuttlingen, Germany) and a special camera (Endovision Telecam SL, Storz, Tuttlingen, Germany) specifically tailored for the detection of PPIX fluorescence induced by 5-ALA (28, 29). Violet-blue light (375-440 nm) serves as the excitation source, with a red channel displaying the PPIX fluorescence, a green channel displaying autofluorescence and an optional blue channel displaying a portion of the excitation light reflected from the tissue surface. Lesion detection can be accomplished through observation of increased red-to-green or red-to-blue contrast.
Endoscopic Applications
In a study of 111 BE patients presented in abstract form, the LIFE system achieved a sensitivity of 90% for identifying patients with HGD and early ACA, relative to a sensitivity of 66% obtained with WLE (30). However, the enthusiasm for the LIFE device was recently curbed by two studies demonstrating its limited diagnostic utility in BE (31, 32). Egger et al. (31) assessed biopsies targeted by LIFE relative to those obtained by the standard surveillance approach (4 quadrant biopsies every 2 cm) in 35 BE patients. The biopsy-related sensitivity and specificity of LIFE for diagnosing HGD or ACA were 25% and 91%, respectively, and its sensitivity for LGD was only 13%. With regard to patients, sensitivity and specificity for dysplastic/cancerous BE versus non-dysplastic BE were 59% and 78%, respectively. Similarly, a randomized cross-over study of 50 BE patients failed to show any benefit of LIFE over conventional biopsy surveillance, with a 20% failure rate in detecting patients with HGD or early ACA (32). The authors' experience with the LIFE system parallels that of the above-mentioned studies in that the device occasionally diagnosed lesions containing HGD that were occult to WLE, but the columnar-lined esophagus routinely produced a false positive (red) fluorescence image (Fig. 4) , making identification of dysplastic lesions within the Barrett's segment difficult. Improvements in LIFE technology are currently underway, including the incorporation of reflectance as a measure to decrease false-positive fluorescence and the development of fluorescence image algorithms specifically targeting BE instead of using those that were originally constructed for colonic pathology.
Because the autofluorescence intensity of tissue is relatively low, photosensitizers such as 5-ALA have been used in an effort to enhance the diagnostic accuracy of fluorescence imaging in BE, but this has yet to be proved in large diagnostic trials (33) (34) (35) . Recently, fluorescence imaging using the Storz system was assessed in 47 BE patients who were given 5-ALA as part of a dose-ranging study (33). Fluorescence imaging performed 4-6 h following administration of 5-ALA (10-30 mg/kg orally) showed relatively high sensitivity (80-100%) but poor to fair specificity (27-56%) for the detection of dysplastic lesions, while imaging 1-2 h following local sensitization with 5-ALA (500-1000 mg spray) demonstrated moderate sensitivity (60%) and specificity (70%). Two patients with early ACA and one with dysplasia were solely detected by fluorescence imaging. Side effects from 5-ALA were limited to nausea and vomiting in four patients and transient elevations in liver enzymes in two. Mild skin photosensitivity was observed only in patients receiving 20-30 mg/kg of 5-ALA orally. False-positive fluorescence was induced mainly by inflammation, bile and metaplasia, explaining the low specificity values obtained in this study and others. Local sensitization is also not practical since two endoscopies are required. Ortner et al. (34) evaluated both fluorescence spectroscopy and imaging following topical spray of 5-ALA (500 mg) in 42 BE patients. Of 36 patients with negative WLE, 4 (11%) had dysplastic or malignant lesions identified by fluorescence spectroscopy and imaging. Fluorescence imaging achieved a sensitivity of 92% but a specificity of 32% in detecting these lesions, whereas spectroscopy demonstrated a sensitivity of 76% and a specificity of 74%. The complementary use of both tech-niques (multi-modal approach) appeared to improve the detection rate of these lesions and to decrease the number of biopsies required for optimal diagnosis.
The findings to date suggest that fluorescence imaging aided by 5-ALA may enhance the detection of dysplastic or cancerous lesions occult to WLE, albeit at the expense of specificity. However, randomized trials comparing fluorescence imaging after sensitization with 5-ALA to standard endoscopic surveillance are mandatory to determine whether a true benefit exists. Moreover, fluorescence imaging with 5-ALA and autofluorescence imaging share similar limitations in that a relatively high number of false-positives can occur due to confounding factors, such as inflammation and metaplasia itself. It is thus unclear whether fluorescence imaging aided by an exogenous agent confers any tangible diagnostic advantage over autofluorescence, at least with regard to the use of 5-ALA in BE. Still, the future of fluorescence imaging in BE and other sites likely will rely on the development of highly selective "fluorescent contrast agents", for example, via conjugation of a fluorophore dye to a monoclonal antibody, enzyme or other dysplastic/tumor-targeting moiety (7). This intriguing approach, however, will necessitate much work regarding identification of key cellular or molecular targets, development of specific fluorescent molecular markers, and demonstration of its in vivo feasibility, efficacy and safety.
Diffuse Reflectance Spectroscopy
Principles and Instrumentation
An elastic scattering event redirects incident photons without changing their wavelengths. Light emerging from the tissue surface after having been scattered multiple times is said to be diffusely reflected. Diffusely reflected light consists of photons that have been scattered mostly by deeper elements within tissue, in particular, extracellular matrix constituents of connective tissue such as collagen (36). Changes in tissue constituents that are associated with disease progression can thus be detected in the diffuse reflectance spectra. These spectra are also sensitive to absorption events by chromophores, such as hemoglobin, which will reduce the intensity of the diffusely reflected light. Diffuse reflectance spectroscopy (DRS) thus provides diagnostic information about the structural composition of tissue, primarily targeting elements originating from the stroma (36).
The basic instrumental set-up for DRS is similar to that of Figure 2 , but the optical design is simpler and lower in cost relative to fluorescence. Instead of a laser, a white-light source, such as a xenon arc lamp, is used. The spacing between the excitation and collection fibers within the probe determines the sampling depth, with fibers that are spaced further apart probing deeper into tissue (36). Similar to fluorescence spectra, diffuse reflectance spectra can be collected in less than 1 s.
Endoscopic Applications
A recent study examined diffuse reflectance spectra collected from 16 BE patients, which included sites from 26 NDBs, 7
LGDs and 7 HGDs. Logistic regression analysis of the spectra distinguished HGD from NDB and LGD with 86% sensitivity and 100% specificity. The sensitivity and specificity for differentiating dysplastic (LGD and HGD) from NDB sites were 79% and 88%, respectively (14). Another study reported by the same group used artificial neural net-works and hierarchial cluster analysis to analyze spectra obtained from 27 BE patients. Dysplastic and cancerous sites were separated from non-dysplastic tissues with 90-95% sensitivity and 85-90% specificity (36). These results, while promising, require prospective validation using a larger data set to gain a more accurate assessment of the diagnostic potential of DRS in BE.
Light Scattering Spectroscopy
Principles and Instrumentation
Light scattering spectroscopy (LSS) uses diffuse reflectance spectra to assess the morphology of the critical layer of interest in BE, the epithelium. Reflectance spectra contain both diffusely reflected (multiply scattered) and singly back-scattered light. The singly back-scattered spectrum is diagnostically important because its spectral features have been shown to correlate with the size and density of nuclei in the uppermost epithelial cells (37-39). In essence, LSS provides similar information that pathologists use to diagnose dysplasia, i.e., nuclear enlargement and crowding, which are among the most important indicators of dysplasia. The singly back-scattered light, however, makes up only a small fraction (2-5%) of the reflectance spectrum, but can be extracted via mathematical modeling (37) or with the use of polarized light (38). The diagnostic potential of LSS has been demonstrated in a variety of epithelial tissues (39), and there is promise for an LSSbased imaging system in the future (40).
Endoscopic Applications
Wallace et al. (41) recently assessed in vivo LSS in 13 patients with BE. A site was classified as dysplastic if more than 30% of the nuclei were enlarged, defined as exceeding 10 µm in diameter by LSS criteria. LSS achieved 90% sensitivity and 90% specificity for identifying LGD and HGD. In addition, there was better inter-observer agreement between LSS and the average histopathologic diagnoses, than between the individual pathologists and the average diagnosis of their colleagues. The same research group in a separate study of 16 patients used a diagnostic algorithm based on both nuclear enlargement and crowding to separate dysplastic from nondysplastic sites with 93% sensitivity and 96% specificity. Using the same information but a different diagnostic threshold, HGD was differentiated from NDB and LGD with 100% sensitivity and 91% specificity (14). These proof-of-principle studies suggest LSS can reliably identify Barrett's dysplasia in vivo. Similar to DRS, further studies of LSS are required to confirm these findings on a larger patient cohort, to determine the ability of LSS to differentiate dysplasia based on its severity, and to assess for the effects of micro-structural mimickers of dysplasia, such as inflammatory/reactive cells. Raman spectroscopy (RS) provides information about molecular vibrations and rotations which can be used for sample identification. The technique uses a monochromatic light source (i.e., laser) for tissue excitation and detects inelastically scattered light. During this process, a tiny amount of the scattered light undergoes wavelength shifts relative to the laser wavelength due to interactions and energy transfer between the incident photons and tissue molecules. These wavelength shifts correspond to specific vibrational or rotational modes of molecules comprising the sample, and plotting the intensity of the inelastically scattered light as a function of these wavelength shifts results in a Raman spectrum of the tissue.
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Unlike fluorescence or reflectance, Raman spectra of tissue exhibit detailed and narrow spectral features with high molecular specificity, which can potentially translate into better diagnostic accuracy for differentiation of tissue pathology. However, the Raman effect is weak where approximately one incident photon in 10 million is converted to an inelastically scattered photon. The Raman signal is thus easily overwhelmed by elastic scattering or fluorescence, and so requires sensitive and more expensive spectroscopic equipment and filtering techniques for its detection (8, 42, 43) .
A range of excitation wavelengths (UV to infrared) can be used in RS since the wavelength shifts are the same, irrespective of the incident wavelength chosen. Although UV excitation can amplify Raman signals via resonance enhancement, UV Raman is unlikely to be approved for clinical use in vivo because of its mutagenic potential. The use of excitation wavelengths in the visible range is also impractical due to generation of an overwhelming fluorescence signal. Currently, near-infrared laser light (785 to 830 nm) is selected as an optimal trade-off between higher sensitivity of available CCD detectors at shorter wavelengths and lower background interference (i.e., fluorescence) at longer wavelengths. Recently, the in vivo feasibility of near-infrared RS during GI endoscopy was demonstrated (44), and a high diagnostic accuracy was achieved in differentiating adenomatous from hyperplastic colon polyps (45). The reported Raman system uses a 785 nm laser diode, a high-throughput spectrograph, a high sensitivity nearinfrared detector, and filtered fiber-optic probes that significantly suppress confounding background signals such as fluorescence, to collect Raman spectra of sufficient signalto-noise ratio in less than 5 seconds (45).
Endoscopic Applications
Our group has been actively involved in assessing the diagnostic potential of near-infrared RS in BE (46). Figure 5 shows the average in vivo Raman spectra of low-risk (n=31) and high-risk (n=13) Barrett's biopsy samples obtained in 24 patients. Typical tissue Raman peaks are seen, for example, at 1655, 1450, 1310, 1260 and 1003 cm -1 , which can be assigned to molecular vibrational modes of the protein amide I band, the CH 2 bending mode, the CH 2 twisting mode, the protein amide III band and the phenyl ring breathing mode, respectively (47). Visually apparent and unapparent (but potentially discriminatory) spectral differences exist between the two histologic classes of BE throughout the spectral range of interest (900-1800 cm -1 ), which are best handled by multivariate statistical classification techniques.
Here, a well-validated genetic algorithm-based optimal region selection (GA-ORS) (48-50) was used to identify a set of regions within the spectra that optimized the separation of Barrett's tissue classes, which were then input into a supervised classification algorithm derived from linear discriminant analysis (LDA). Unknown spectra can then be classified according to their positions with respect to the discriminant function line. Because of the limited number of samples available, a leave-one-out resampling approach was used in our analysis, in which an LDA classifier is formulated for all remaining spectra and evaluated on the "left-out" spectrum. This is repeated until all spectra have been "leftout," a process which enables cross-validation with all LDA classifiers and generates estimates of sensitivity and specificity. Preliminary spectral prediction of tissue class, based on the leave-one-out GA-ORS/LDA algorithm, achieved 92% sensitivity, 100% specificity, and 98% overall accuracy in classifying Barrett's samples into low-risk or high-risk. These promising results, however, require confirmation on a larger and prospective sample size. Further studies should also address the potential of near-infrared RS for distinguishing between grades of dysplasia in BE. Wavenumber (cm-1) Figure 5 : In vivo mean Raman spectra of Barrett's esophagus. The Raman wavelength shift is conventionally expressed in terms of the difference in wavenumbers (1/wavelength) in units of cm -1 between the incident and scattered light. Spectral features are more detailed in Raman than in fluorescence (see Fig. 1 ).
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Optical Coherence Tomography
Principles and Instrumentation
Optical coherence tomography (OCT) is the optical analogue of ultrasound. The technique uses low-coherence infrared light and an interferometer to produce high-resolution, crosssectional imaging of tissue by measuring the intensity of back-scattered light in near-real-time (51). Unlike ultrasound, a coupling medium is not required and images can be acquired with the OCT probe in proximity or in contact with tissue. The in vivo spatial resolution of 10-25 µm achieved by current endoscopic OCT systems is 10-fold better than that of high-frequency ultrasound. However, the sampling depth is limited to 2 mm (52-56).
Current endoscopic OCT devices are catheter-based (2-2.7 mm in diameter) which fits through the accessory channel of an endoscope (52-56). The three main OCT probe designs allow scanning of the esophagus in a linear (53), transverse (52) or radial (54) fashion. Regardless of the scanning mode, the probed site is limited to a small cross-sectional surface area, and the probe-tissue working distance ideally should be within 1 mm for the OCT images to be in focus. This is difficult to achieve amid a peristaltic esophagus and, in practice, the probe is placed in contact with tissue during image acquisition with the caveat that compression artifacts may be seen.
Endoscopic Applications
OCT imaging of normal squamous esophagus demonstrates a 5-layered structure (52, 56) . In BE, the OCT images are quite variable ranging from a layered structure in some cases to an irregular, inhomogenous surface in others (55, 57). Although visualization of goblet cells, the hallmarks of specialized intestinal metaplasia (SIM), is beyond the resolution of currently available OCT devices, a recent study (57) using the linear scanning OCT system described criteria that were highly predictive of SIM: i) absence of the layered structure of the normal squamous epithelium and the vertical crypt and pit morphology of gastric mucosa; ii) disorganized architecture with inhomogeneous tissue contrast and an irregular mucosal surface; and iii) presence of submucosal glands seen as pockets of low reflectance underneath the epithelial surface. A prospective evaluation found these criteria to be 97% sensitive and 92% specific for SIM, with or without dysplasia. False-positive images usually arise from tissue of the cardia, with or without inflammation (57).
It is however difficult to identify dysplasia using existing endoscopic OCT systems based on morphologic interpretation. The diagnostic performance of the radial OCT device for detecting dysplasia in BE was fair, with a recently reported sensitivity of 69%, a specificity of 71%, and an accuracy of 70% (58). With the linear scanning OCT device, a trend toward increased glandular irregularity was seen with increasing degrees of dysplasia, although this was difficult to interpret in a consistent and accurate fashion (57). Alternatively, a quantitative analysis of the OCT signal seemed to identify HGD with high sensitivity (100%) and specificity (85%) in a small retrospective study, which will require validation on a larger and prospective sample size (59).
Future directions regarding OCT will consist of improving image resolution to sub-cellular levels so that goblet cells and dysplastic nuclei can be identified. Laboratory-based OCT systems using ultrashort pulse lasers have achieved remarkable resolutions of 1-3 µm, which are capable of resolving individual cell nuclei (60). Although these systems are currently impractical for clinical applications, they represent a starting point in developing ultra-high resolution, catheterbased OCT devices for endoscopic use. Other potential advances may include spectroscopic OCT that can provide complementary information on the spectrum of back-scattered light at various tissue levels (61), and Doppler OCT to assess for potential differences in microvasculature associated with dysplastic and nondysplastic BE ( Fig. 6 ) (62).
Multimodal Optical Diagnosis
Recently, a multimodal spectroscopic technique was developed combining fluorescence, diffuse reflectance and light scattering modalities in one system. In a small-scale, proofof-principle study, multimodal spectroscopy proved to be superior to any single spectroscopic technique alone in classifying dysplasia in patients with BE (14) . This is to be expected since the combination of spectroscopic techniques provide complementary information about the biochemical and morphological changes that occur during the development of dysplasia in BE. Indeed, it is anticipated that a multimodal optical technique for disease diagnosis and differentiation will be key to the successful application of optical based modalities in mainstream endoscopic practice.
Photodynamic Therapy
Principles and Instrumentation
PDT causes photochemical injury via light activation of a photosensitizing drug that is preferentially retained in dysplastic or neoplastic tissues. A photosensitizer remains inactive until it is exposed to light of a specific wavelength that can be absorbed by the drug. The drug then enters a high energy triplet state which is transferred to surrounding oxygen thereby creating singlet oxygen. The latter is a reactive molecule that interacts with cellular structures producing cell necrosis. In BE, this is followed by healing and replacement usually with normal squamous mucosa (Fig.  7 ). The primary advantage of PDT in BE over other minimally invasive therapeutic modalities is that the technique allows treatment of a large surface area of the mucosa in a relatively uniform and circumferential fashion.
The most commonly used photosensitizers are hematoporphyrin derivative (HpD), porfimer sodium (Photofrin II) and 5-ALA, which all act essentially as porphyrins and can be activated with 630-635 nm light. 5-ALA-induced PPIX has been shown to be selectively retained within the mucosal layer, which limits the depth of the photodynamic effect. HpD and porfimer sodium are administered intravenously 48 h prior to endoscopy and photoradiation of the Barrett's segment. With regard to 5-ALA, recent pharmacokinetic studies have shown that uptake of the drug is very rapid and the optimal time for photoradiation is approximately 4-5 hours following drug ingestion (63). These photosensitizing agents are generally well tolerated, although patients given 5-ALA may experience nausea and a reversible elevation in their liver enzymes. 5-ALA produced jaundice in one patient (3%) in a recent series (64). A new topical formulation of 5-ALA has been developed that may prevent these side effects, although current application times can be fairly lengthy with maximum PPIX formation after 3 h (65).
A recent report using another topical 5-ALA formulation seems to indicate that this method of delivery is able to eliminate LGD in a small sample of seven patients (66). A disconcerting event, however, was the development of HGD in one patient after treatment, indicating that this form of therapy probably does not work well for HGD.
As mentioned above, porphyrin-based photosensitizers can be activated in the red light region between 630-700 nm. Inexpensive portable diode lasers are now available, which can be purchased at less than half the cost of traditional laser systems. Previously, the commonly used laser systems were tunable dye lasers that are pumped by either argon or frequencydoubled YAG lasers, such as KTP:YAG lasers. These systems produce very large amounts of laser energy but are more difficult to maintain than newer diode systems. They also require larger power sources and cooling systems, while diode lasers are air-cooled and can be powered from typical room outlets.
Photoradiation can be performed by various means, ranging from placement of a diffusing fiber through the working channel of the endoscope to a specialized modified diffuser which is placed via fluoroscopic guidance. The cylindrical diffusing fiber is used most often because of its simplicity, and is visually positioned within the center of the esophagus. Tissue can be treated in stages of 5.0 cm segments, as this is the longest therapeutic window of the fiber that is commercially available. This technique has the disadvantage of being unable to flatten mucosal folds, which may shield some areas from light exposure. In order to minimize this effect, balloon diffusers have been developed which can be passed through the scope (64) or orally (67) diameter balloons may be ideal to flatten the esophageal folds (68). Balloons have a cylindrical diffusing fiber within the center of the balloon, which provides the light to treat the mucosa. In general, the longest balloons utilized have been about 7 cm in length, which corresponds to the length of circumferential mucosa that can be treated at a given session. This restriction is primarily due to chest pain and odynophagia, which develop after therapy. Treatment parameters for PDT of BE with HGD using either HpD or sodium porfimer are similar. Both are activated using red light (630 nm) at a power of 400 mW/cm fiber for a total energy of approximately 200 J/cm fiber. If a delivery device such as a balloon is used, energy requirements are generally less. 5-ALA is usually activated at a slightly longer wavelength (635 nm). After photoradiation, patients usually experience chest pain within 24 hours. The pain can be severe and may require narcotic administration for relief. Dehydration may also be an issue, with some patients requiring intravenous fluids. Nausea is also common after mucosal ablative therapy. Other uncommonly reported complications have included atrial fibrillation and pleural effusions (69, 70). Cutaneous phototoxicity will persist in patients given HpD or porfimer sodium for a period of 1-3 months during which time patients should avoid direct exposure to sunlight. Esophageal strictures can be a major problem since they occur in about 25% of patients treated. Most will require several esophageal dilatations in order to relieve dysphagia.
Endoscopic Applications
Selected studies conducted to date using PDT for ablation of HGD in BE are summarized in Table III (10, 64, 69, (71) (72) (73) (74) .
Most patients appear to have a "downgrading" in dysplasia status from high grade to non-dysplastic Barrett's in 77-100% of cases. However, elimination of the Barrett's segment is much more difficult to achieve with only about a third of patients demonstrating complete eradication of the Barrett's segment with a single therapy. The majority will persist with residual islands of intestinal metaplasia, which can be treated with additional courses of PDT, ablated with other modalities such as an Nd:YAG laser (67) or argon plasma coagulator (69), or simply observed if there is no evidence for residual dysplasia. PDT with 5-ALA has also been used in BE with
LGD with 100% eradication of dysplasia and variable regression of the metaplastic segment in 88% of patients (75). It is apparent, however, that 5-ALA is unable to eliminate all of the Barrett's intestinal metaplasia in any patient. This was supported by a recent study which showed that only superficial cancers (< 2mm) could be eliminated using 5-ALA as a photosensitizer (76). In order to treat deeper lesions, this group has used mTHPC, which is a chlorin compound (related to porphyrin rings) with absorption in the longer red wavelength range (and hence deeper tissue penetration) (64). In addition, it is common (up to a third of biopsies) to find residual Barrett's mucosa underlying endoscopically normal appearing squamous mucosa after ablative therapy with 5-ALA PDT (77). A concerning issue about residual Barrett's tissue has been the persistence of genetic abnormalities in the mucosa despite histologic improvement (78). At the current time, PDT is used primarily in BE patients at greatest risk for cancer, i.e. those with dysplasia. BE with HGD appears to respond to PDT using either porfimer sodium or 5-ALA, although complete elimination of the Barrett's mucosa seems to be more common with the former. The goal of therapy with PDT should be total eradication of the Barrett's mucosa.
Novel photoradiation devices and lasers should make the treatment of BE much simpler, although side effects are significant with current photosensitizers, such as porfimer sodium. Better photosensitizers that are highly selective for dysplastic BE and associated with minimal skin phototoxicity and stricturing effects are needed.
Summary
The future of optical-based modalities for diagnosis and therapy of BE remains bright. Optical diagnostic techniques are promising modalities for enhancing the surveillance and detection of dysplastic or early neoplastic lesions in BE. However, much work remains to be done with respect to optimization and assessment of these technologies in prospective, large-scale clinical trials. Ultimately, the optimal technique may be a combination of optical modalities (multimodal optical diagnosis) that will maximize diagnostic sensitivity and specificity. For instance, a lesion could be detected by a wide area surveillance technique such as fluorescence imaging, and further characterized (or graded) by a spectroscopic technique, such as fluorescence, Raman and/or light scattering. From the therapeutic standpoint, the use of PDT is emerging as a promising alternative to surgery for eradicating dysplastic BE, although photosensitizers with better selectivity, efficacy and toxicity profiles are needed.
